文献速递血栓与止血

血友病A标准预防仍存未满足需求:换用efanesoctocog alfa后改善

Unmet needs despite standard-of-care prophylaxis in hemophilia A: improved outcomes after switching to efanesoctocog alfa.
PubMed 文献 · Blood Adv · 2026-01-01

法国 compassionate access 框架下多中心研究纳入50例血友病A患者(84%重型,中位年龄31岁,9例有抑制物史),其中46%因突破性出血(88%)等从emicizumab转换。每周efanesoctocog alfa预防中位随访9个月,总人群治疗性出血减少89%(P<.001),关节出血减少85%(P<.001),无新发抑制物。但本地一期法(OSA)与中心化药物校准CSA的谷浓度存在显著差异(中位14 vs 7 IU/dL,P<.001)。

要点

  • efanesoctocog alfa每周预防可显著减少治疗性出血和关节出血,包括既往emicizumab治疗患者。
  • 标准预防下仍有未满足需求,46%患者因突破性出血等从emicizumab转换。
  • 本地OSA与药物校准CSA监测谷浓度差异显著,实验室监测面临挑战。

核心结论

  • efanesoctocog alfa每周预防有效解决复杂未满足需求,包括emicizumab治疗患者,但本地OSA与药物校准CSA的监测差异需关注。

研究设计与样本

  • 法国compassionate access授权框架下多中心研究,纳入50例血友病A患者(84%重型,中位年龄31岁,9例有抑制物史),中位随访9个月。

主要发现

  • 总人群治疗性出血减少89%(P<.001),关节出血减少85%(P<.001),探索性亚组(包括既往emicizumab患者)结果一致。
  • 无新发抑制物发生。
  • 中心化药物校准CSA(n=31)中位第7天谷浓度为7 IU/dL;配对比较(n=18)本地OSA中位谷浓度14 IU/dL vs 中心化CSA 7 IU/dL(P<.001)。

关键数值与推荐

  • 54%患者从FVIII预防转换,46%从emicizumab转换,转换原因包括持续突破性出血(88%)和复杂多因素场景(76%)。

临床怎么用

  • efanesoctocog alfa每周预防可用于标准预防下仍有突破性出血的血友病A患者,包括emicizumab治疗者。
  • 监测谷浓度时需注意本地OSA与药物校准CSA的结果差异,建议采用药物校准CSA。

局限性

  • 样本量较小(50例),随访时间较短(中位9个月),为真实世界compassionate access研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Efanesoctocog Compassionate Hemophilia study (Méthodologie de Référence-004, number DEC24-269) provides a real-world evaluation of efanesoctocog alfa (efa), a first-in-class ultralong-acting factor VIII (FVIII) concentrate, within the French compassionate access authorization (CAA) framework. It aims to characterize the unmet medical needs leading to CAA requests and evaluate the hemostatic efficacy and biological monitoring of efa prophylaxis. This multicenter study included 50 patients with hemophilia A (84% severe; median age, 31 years), including 9 with inhibitor history. Although 54% of patients switched from FVIII prophylaxis, 46% of patients transitioned from emicizumab because of persistent breakthrough bleeding (88%) and complex multifactorial scenarios (76%). Over a median follow-up of 9 months, weekly efa prophylaxis resulted in a significant 89% reduction in treated bleeds (P< .001) and an 85% reduction in joint bleeds (P< .001) in the total population. This clinical benefit remained consistent across exploratory subgroups, including patients who were previously on emicizumab. No new-onset inhibitors occurred. Biologically, the median centralized day-7 trough level was 7 IU/dL using a drug-calibrated bovine chromogenic substrate assay (CSA, n = 31). However, a significant discrepancy was observed in paired comparisons (n = 18), where local 1-stage assays (OSAs) yielded a median trough level of 14 IU/dL, compared with a centralized CSA median of 7 IU/dL (P< .001). Notably, this divergence occurred across various local reagents considered acceptable alternatives to Actin FSL for efa monitoring. In conclusion, efa effectively addresses complex unmet needs, including those of emicizumab-treated patients. However, the discrepancy between results of local OSAs and drug-calibrated CSA highlights challenges in laboratory monitoring.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Rauch A, Maynadié H, Desage S, et al. Unmet needs despite standard-of-care prophylaxis in hemophilia A: improved outcomes after switching to efanesoctocog alfa. Blood Adv. 2026. PMID: 42448323. doi:10.1182/bloodadvances.2026020401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。